Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...
3d
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday
Moderna said it expects 2025 revenue of approximately $1.9 billion, which is $100 million above the midpoint previously ...
Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while ...
Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the ...
HHS Secretary Robert F. Kennedy Jr. doesn't believe mRNA vaccines for COVID-19 and flu work, so funding is shifting to virus-based vaccines Moderna's stock fell Wednesday after Health and Human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback